Back

Effect of dronedarone versus placebo on atrial fibrillation progression: a post-hoc analysis from ATHENA trial

29 August 2022 (15:15 - 15:55)
Organised by:
Congress Presentation Part of: Atrial fibrillation: rate or rhythm control Rhythm Control, Antiarrhythmic Drugs ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Madelene Carina Blomstrom-Lundqvist

Orebro University Hospital, Orebro (Sweden)

5 More presentations in this session

Presentation thumbnail
Association between early rhythm control and the risk of dementia in patients with atrial fibrillation and prior history of stroke: a nationwide population-based study
Doctor S. Lee (Seoul, KR)
Abstract Slides
Presentation thumbnail
Dronedarone versus sotalol in patients with atrial fibrillation: a systematic literature review and network meta-analysis
Professor J. Camm (London, GB)
Abstract Slides
Presentation thumbnail
Holistic approach of ablation versus antiarrhythmic drugs for efficacy, safety, and quality of life improvement in rhythm control of atrial fibrillation: a meta-analysis of randomized trials
Mr G. Prana Jagannatha (Denpasar, ID)
Abstract Slides
Presentation thumbnail
Sex differences in the use of rhythm control strategies in patients with atrial fibrillation in FinACAF study
Ms K. Kalatsova (Helsinki, FI)
Abstract Slides
Presentation thumbnail
Prevalence of modifiable risk factors and related poor cardiovascular outcomes following atrial fibrillation ablation
Doctor K. Stout (Omaha, US)
Abstract Slides

Access the full session

Session thumbnail
Atrial fibrillation: rate or rhythm control

The Event

Event poster

ESC Congress 2022

29 August 2022 15:15 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources